RT Journal Article
T1 Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.
A1 Bukkems, Vera
A1 Necsoi, Coca
A1 Tenorio, Carmen Hidalgo
A1 Garcia, Coral
A1 Rockstroh, Jürgen
A1 Schwarze-Zander, Caroline
A1 Lambert, John S
A1 Burger, David
A1 Konopnicki, Deborah
A1 Colbers, Angela
K1 HIV
K1 cobicistat
K1 elvitegravir
K1 pharmacokinetics
K1 pregnancy
AB This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.
YR 2020
FD 2020
LK http://hdl.handle.net/10668/15427
UL http://hdl.handle.net/10668/15427
LA en
DS RISalud
RD Apr 8, 2025